期刊文献+

特发性肺动脉高压的治疗进展 被引量:1

下载PDF
导出
摘要 特发性肺动脉高压(PAH)是一种病因未明的,排除了其它可能病因的平均肺动脉压静息时大于25mmHg或运动时大于30mmHg的疾病。本病病因不清,预后差,确诊后未治疗者平均生存期为2.8年,临床表现为乏力、气息、咳嗽、咯血、周围性紫绀、胸痛及心功能不全等剐。这是一种少见疾病,无特异临床症状,估计发病率为每年每百万人口2-3例,以女性为主,男女比例为l:3-4。
作者 冯兵 曹斌
出处 《承德医学院学报》 2011年第4期424-426,共3页 Journal of Chengde Medical University
  • 相关文献

参考文献22

  • 1Pass SE,DusingML.Current and emerging therapy for primary pulmonary hypertension[J].Ann Pharmacother,2002,36(9):1414-1423.
  • 2Rubin LJ.Pulmonary hypertension[A].In:Murray JF Nadel Textbook of respiratory medicine[C].3rded.Philadephia,Saunders,2000.1524-155.
  • 3Femandez A,Guerra MF,Camino E,et al.New etiopathogenioc,diagnostic and therapeutuc aspects in primary pulmonaryhypertension[J].An Med Interna,1995,12(6):294-298.
  • 4周爱卿.先天性心脏病并重症肺动脉高压的性质评价[J].实用儿科临床杂志,2003,18(11):856-858. 被引量:6
  • 5柳志红,秦春常.欧洲心脏病学会肺动脉高压指南解读[J].中国实用内科杂志,2007,27(4):243-246. 被引量:23
  • 6Rich S,Kaufimann E,Levy PS.The effect of high dose of calcium-chamnal blockers on sutvival in primary pulmonary hypertension[J].N Engl J Med,1992,327:76.
  • 7Humbert M,Sitbon O,Simonneau G.Treatment of pulmonary arterial hypertensiOn[J].N Engl J Med,2004,351(14):1425-1436.
  • 8Ruhln IJ.Primary pulmonary hypertension[J].N Engl J Med,1997,336,111-117.
  • 9Moncada S,Palmer RM,Higgs EA.Nitric oxide:physiology,pathoph ysilolgy and pharmacology[J].Pharmacol Rev,1991,43:109-42.
  • 10Owen NE.Prostacyclin can inhibit DNA synthesis in vascular smooth muscle cells[A].In:Bailey JM.Prostaglandins,leukogiens and lipoxins[C].New Yord:Plenum Pess,1995.193-204.

二级参考文献42

  • 1薛全福,谢剑鸣.常压缺氧性大鼠肺动脉高压模型的建立[J].中华结核和呼吸杂志,1989,12(6):350-352. 被引量:157
  • 2杨小东,陈文彬,陈俊杰.内皮素在低氧性肺动脉高压大鼠肺内表达和水平变化的研究[J].中华内科杂志,1996,35(11):734-737. 被引量:16
  • 3向一青.益气化瘀法治疗肺胀112例[J].河北中医,2006,28(11):824-825. 被引量:3
  • 4[1]Rich S,Kaufman E,Levy P.The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension[J].N Engl J Med,1992,327(1):76.
  • 5[2]Barst RJ,Rubin LJ,Long wA,et al.A comparison of continuous intravenous eporprostenol(prostacyclin)with conventional therapy for primary pulmonary hypertension[J].N Engl J Med,1996,334(5):296-302.
  • 6[3]McLaughlin V,Genthner D,Panella M,et al.Reduction in pulmonary vascular resistance with long-term epoprostenol(prostacyclin)therapy in primary pulmonary hypertension[J].N Engl J Med,1998,338(5):273-277.
  • 7[4]Shapiro SM,Oudiz RJ,Cao T,et al.Primary pulmonary hypertension:improved long-term effects and survival with continuous intravenous epoprostenol infusion[J].J Am Coll Cardiol,1997,30(2):343-349.
  • 8[5]Badesch D,Tapson V,McGoon M,et al.Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease[J].Ann Intern Med,2000,132(6):425-434.
  • 9[6]Sebbag I,Rudski LG,Therrien J,et al.Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension[J].Am J Cardiol,2001,88(9):1060-1063.
  • 10[7]Simonneau G,Barst RJ,Galie N,et al.Continuous subcutaneous infusion oftreprostinil,a prostacyclin analogue,in patients with pulmonary arterial hyperten-sion:a double-blind,randomized,placebo-controlled trial[J].Am J Respir CritCare Med,2002,165(6):800-804.

共引文献63

同被引文献28

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部